New Delhi, May 27 -- : Dismissing the reports of health risks from Hydroxychloroquine (HCQ) as per simmering reports cited by the World Health Organisation (WHO), Shekher Mande, Director General of the Council of Scientific and Industrial Research (CSIR), India, said on Wednesday that the study related to the anti-malarial drug, which suspended the drug usage, is not a randomised clinical trial and rather only an analysis of hospital registers around the world.
The WHO, on Sunday, announced for a temporary suspension of clinical trials of hydroxychloroquine, which has been used for the treatment of COVID-19 patients, after a study published in the online medical journal The Lancet found that the use of the drug increased the risk of death ...